Tykerb FDA Approval History
FDA Approved: Yes (First approved March 13, 2007)
Brand name: Tykerb
Generic name: lapatinib ditosylate
Dosage form: Tablets
Treatment for: Breast Cancer
Tykerb (lapatinib) is a kinase inhibitor indicated for the combination treatment of patients with advanced or metastatic breast cancer.
Development Timeline for Tykerb
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.